<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332952</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiologia-002</org_study_id>
    <nct_id>NCT04332952</nct_id>
  </id_info>
  <brief_title>Damage and Renal Clearance of Glycocalyx in Cardiac Surgery</brief_title>
  <acronym>GlycoCarSur</acronym>
  <official_title>Damage and Renal Clearance of Glycocalyx in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Ayala León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Beneficencia Espanola de Puebla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The glycocalyx is a component of the vascular endothelium that currently plays a relevant
      role in the modified Starling theory.

      The manipulation of the heart during cardiac surgery stimulates the release of the
      natriuretic atrial peptide, which causes endothelial wear in patients undergoing
      extracorporeal circulation. Dilation of the atrium produces natriuretic atrial peptide, which
      reduces plasma volume by increasing renal excretion and vascular permeability. The atrial
      peptide degrades the surface of the coronary endothelium, causing loss of the side cam
      protein nucleus. This study investigates the relationship between clamping time in cardiac
      surgery and the clearance of endothelial inflammation markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracorporeal circulation time</measure>
    <time_frame>2 hours</time_frame>
    <description>Duration of Extracorporeal Circulation in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic clamping time</measure>
    <time_frame>2 hours</time_frame>
    <description>Duration of aortic clamping time in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyaluronic acid levels in blood before surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of hyaluronic acid in blood before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyaluronic acid levels in blood after surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of hyaluronic acid in blood after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyaluronic acid levels in urine before surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of hyaluronic acid in urine before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyaluronic acid levels in urine after surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of hyaluronic acid in urine before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sydecan -1 levels in blood before surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of Sydecan -1 in blood before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sydecan -1 levels in blood after surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of Sydecan -1 in blood after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sydecan -1 levels in urine before surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of Sydecan -1 in urine before surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sydecan -1 levels in urine after surgery</measure>
    <time_frame>30 minutes</time_frame>
    <description>Quantity of Sydecan -1 in urine after surgery</description>
  </primary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Glycocalyx</condition>
  <condition>Cardio-Renal Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the selection criteria undergoing cardiac surgery for a single valve
        change or replacement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Patients who underwent cardiac surgery for a single valve change or replacement

        Exclusion Criteria:

          -  Stage 3 renal failure patients

          -  Patients with a previous diagnosis of hematological malignancy

          -  Patients undergoing pulmonary valve change surgery.

          -  Patients undergoing Bentall and Bono surgery.

          -  Patients Undergoing Coronary Artery Bypass Surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Beneficencia Española de Puebla</name>
      <address>
        <city>Puebla</city>
        <zip>72090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Beneficencia Espanola de Puebla</investigator_affiliation>
    <investigator_full_name>Miguel Ayala León</investigator_full_name>
    <investigator_title>cardiovascular critical care unit director</investigator_title>
  </responsible_party>
  <keyword>Renal clearance</keyword>
  <keyword>Glycocalyx</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

